What the FDA labels say about taking them together
Carbamazepine and lemborexant
Lemborexant's FDA label of February 24, 2025 names carbamazepine in its drug interactions section; the carbamazepine labels PlainMeds reads (3) do not name lemborexant. The lemborexant label: “Concomitant use with a strong or moderate CYP3A inducer decreases lemborexant exposure, which may reduce DAYVIGO efficacy.”
Check it at the source: the carbamazepine FDA label on DailyMed (effective August 20, 2026, Novartis Pharmaceuticals Corporation); the lemborexant FDA label on DailyMed (effective February 24, 2025, Eisai Inc.).
What does the carbamazepine label say about lemborexant?
Carbamazepine's label (effective August 20, 2026) and its 2 other brand-application labels do not name lemborexant in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tegretol), Novartis Pharmaceuticals Corporation, effective August 20, 2026 (SPL set 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053), via openFDA; the full label on DailyMed
What does the lemborexant label say about carbamazepine?
Lemborexant label, drug interactionsStrong and Moderate CYP3A Inducers Clinical Impact: Concomitant use with a strong or moderate CYP3A inducer decreases lemborexant exposure, which may reduce DAYVIGO efficacy. Intervention: Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inducers [see Dosage and Administration ()]. Examples: Strong CYP3A inducers: rifampin, carbamazepine, St. John’s wort Moderate CYP3A inducers: bosentan, efavirenz, etravirine, modafinil
Source: FDA drug label (DAYVIGO), Eisai Inc., effective February 24, 2025 (SPL set 7074cb65-77b3-45d2-8e8d-da8dc0f70bfd), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Carbamazepine | Lemborexant | |
|---|---|---|
| Labeled for | Bipolar disorder, Seizures and epilepsy | Insomnia |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.119 per tablet 200 mg tablet | $11.57 per tablet 10 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once